Abstract

Summary: This issue's Small Animal Review features studies that seek to answer the long-standing question of the role of angiotensin-converting enzyme inhibitors in preclinical myxomatous mitral valve disease. Previous recommendations have suggested they are beneficial for use in dogs before they present with clinical signs, if cardiomegaly was present on radiographic or ultrasonographic examination. Systematic reviews and meta-analyses are considered the highest form of evidence and they can be helpful in answering questions when single trials do not have sufficient power to be conclusive.samples in measuring exposure to aromatic amines.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call